GlassScriptPhysician profile
Haiyun Wang
NPI 1679749121
$15,275.74
in general payments reported to CMS, 2019-2025
26 companies · $9,149 in 2025
The $9,149 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $367 · 2023: $1,630 · 2024: $4,130 · 2025: $9,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,333 · Grant: $350 · Education: $216 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,810.00 |
| Food and Beverage | $1,332.84 |
| Grant | $350.00 |
| Education | $216.20 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,014.76 | 2022-2025 | Imfinzi, Truqap, Enhertu |
| Stemline Therapeutics INC. | $4,960.00 | 2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $1,098.50 | 2022-2023 | Fotivda |
| Beigene USA, INC. | $721.49 | 2022-2024 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $254.57 | 2022-2023 | Enhertu |
| Sobi, INC | $210.65 | 2024 | |
| Abbvie INC. | $157.88 | 2025 | |
| Tempus Ai, INC | $107.10 | 2025 | Xt Cdx |
| Genentech USA, INC. | $106.90 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $93.50 | 2022 | |
| Astellas Pharma US INC | $92.77 | 2023-2025 | Xospata |
| Accord Healthcare, INC. | $88.66 | 2025 | |
| Emd Serono, INC. | $61.87 | 2022 | |
| Rigel Pharmaceuticals, INC. | $43.35 | 2023-2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $43.27 | 2022-2023 | Reblozyl |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $41.84 | 2022-2024 | |
| Array Biopharma INC | $28.68 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $26.44 | 2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $25.44 | 2022 | |
| Spectrum Pharmaceuticals INC. | $18.98 | 2024 | Rolvedon |
| Pfizer INC. | $17.12 | 2024 | |
| Eisai INC. | $13.35 | 2024 | |
| Adc Therapeutics America, INC. | $13.18 | 2023 | |
| Fresenius Kabi USA, LLC | $13.11 | 2024 | Stimufend |
| Eusa Pharma (US) LLC | $12.47 | 2022 | |
| Secura Bio, INC. | $9.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haiyun Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.